ACM
IRWD icon

Anfield Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Anfield Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,433
Closed -$30.1K – 79
2022
Q4 		$30.1K Buy
2,433
+634
+35% +$7.19K 0.01% 77
2022
Q3 		$19K Buy
1,799
+58
+3% +$658 0.01% 84
2022
Q2 		$20K Buy
1,741
+232
+15% +$2.73K 0.01% 89
2022
Q1 		$19K Buy
1,509
+825
+121% +$9.46K 0.01% 90
2021
Q4 		$8K Buy
684
+633
+1,241% +$7.77K ﹤0.01% 97
2021
Q3 		$1K Buy
+51
New +$659 ﹤0.01% 116

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Anfield Capital Management's IRWD Position: Q1 2023 in Review

Anfield Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2023, closing a stake of 2,433 shares — an estimated $30.1K sold.

Anfield Capital Management first reported a position in IRWD in Q3 2021 and held it in 6 quarters. The position peaked at $30.1K in Q4 2022. 254 funds tracked by Wall St. Rank hold IRWD as of Q1 2023.

  • Anfield Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Anfield Capital Management sold 2,433 Ironwood Pharmaceuticals shares in Q1 2023, an estimated $30.1K.
  • Anfield Capital Management first reported a position in Ironwood Pharmaceuticals in Q3 2021 and held it in 6 quarters.
  • Anfield Capital Management's Ironwood Pharmaceuticals position peaked at $30.1K in Q4 2022.
  • 254 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2023.

Based on Anfield Capital Management's 13F filing for Q1 2023, filed 4 May 2023.